Brief: Applied Molecular Transport Announces Top-Line Phase 2 Results From Lombard Monotherapy Trial Of Oral Amt-101 In Patients With Moderate-To-Severe Ulcerative Colitis

Applied Molecular Transport.

22/12/2022 22:24

Dec 22 (Reuters) - Applied Molecular Transport Inc.
 AMTI.O :
    * APPLIED MOLECULAR TRANSPORT ANNOUNCES TOP-LINE PHASE 2
RESULTS
FROM LOMBARD MONOTHERAPY TRIAL OF ORAL AMT-101 IN PATIENTS WITH
MODERATE-TO-SEVERE ULCERATIVE COLITIS
    * APPLIED MOLECULAR TRANSPORT INC. - SIMILAR CLINICAL
REMISSION
RATES OBSERVED IN PATIENTS RECEIVING AMT-101 MONOTHERAPY
COMPARED TO PLACEBO AT WEEK 12
    * APPLIED MOLECULAR TRANSPORT INC. - STRONG CASH POSITION OF
$76M
REPORTED IN Q3 2022
    * APPLIED MOLECULAR TRANSPORT INC. - EXPLORING STRATEGIC
PARTNERSHIP OPTIONS TO ADVANCE AMT-101 INTO PHASE 3 IN PATIENTS
WITH CHRONIC POUCHITIS
    * APPLIED MOLECULAR TRANSPORT INC. - AMT-101 WAS
WELL-TOLERATED
    * APPLIED MOLECULAR TRANSPORT INC. - PLANNED PHASE 1B TRIAL
FOR
THE COMPANY’S SECOND CLINICAL ASSET, AMT-126, IN UC PATIENT

Further company coverage:  AMTI.O 
 ((Reuters.Briefs@thomsonreuters.com;))